Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events
Weihong Zhang(Tianjin Medical University Cancer Institute and Hospital), Xiubao Ren(Tianjin Medical University Cancer Institute and Hospital), Runmei Li(Tianjin Medical University Cancer Institute and Hospital), Yuan Meng(Ministry of Agriculture), Yang Wang(Tianjin Medical University Cancer Institute and Hospital), Weijiao Du(Tianjin Medical University Cancer Institute and Hospital), Liang Liu(Tianjin Medical University Cancer Institute and Hospital), Li Zhou(Hunan Normal University), Lin Yang(Guangxi Medical University), Ying Han(Fujian University of Traditional Chinese Medicine), Meng Shen(Soochow University), Xinwei Zhang(Nanjing Municipal Center for Disease Control And Prevention), Yanjuan Xiong(Tianjin Medical University Cancer Institute and Hospital)
Cited by 9
Related Papers
Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
|Cancer Cell|2008|917
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
|Frontiers in Pharmacology|2019|287
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
|Chinese Journal of Cancer Research|2019|126
Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2
|Nature Communications|2021|117